Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > AACR posters?

<< Previous

Bullboard Posts

Next >>

Comment by palinc2000on Mar 17, 2021 5:26pm

122 Views

Post# 32819400

RE:RE:RE:AACR posters?

The current SP does not even fully value the 2 drugs presently being sold,,,,,Sales are finally gaining traction and pretty soon the market will have a reason to project higher sales which imo should be enough to propel the SP to 6.66$ US in the short term.....
.
Add to that some value to the pipeline which should increase with each bit of good news and or advancement

<< Previous

Bullboard Posts

Next >>

Global Tungsten Market and Supply Security